CSIR launches ayurvedic anti-diabetic drug

Developed jointly by NBRI and CIMAP, the research units of CSIR situated at Lucknow, BGR-34 has been economically priced at Rs 5 per tablet as compared to the latest DPP4 inhibitors, globally.

By: Express News Service | Pune | Published: May 27, 2016 1:19 am
calcium pills, side effects, health news, risk to elders BGR-34 has been designed for type-2 diabetes mellitus and scientifically validated for its efficacy and safety

The country’s first scientifically-confirmed anti-diabetes Ayurvedic drug with DPP4 inhibitory activity, BGR-34 (Blood Glucose Regulator-34), was launched by Council for Scientific and Industrial Research (CSIR) recently at a press conference in Pune. BGR-34 has been designed for type-2 diabetes mellitus and scientifically validated for its efficacy and safety, said A K S Rawat, the principal senior scientist, CSIR-National Botanical Research Institute (NBRI).

Sanjeev Kumar Ojha, senior scientist, CSIR- NBRI, Lucknow, Dayanandan Mani, senior scientist, CSIR-Central Institute of Medicinal and Aromatic Plants (CIMAP), Lucknow, Medha Kulkarni, vice principal, D Y Patil Ayurvedic College and Research Centre, Pune, and S P Srivastav, director, AIMIL Pharmaceuticals (India) Ltd, were also present on the occasion.

Share This Article
Share
Related Article

Developed jointly by NBRI and CIMAP, the research units of CSIR situated at Lucknow, BGR-34 has been economically priced at Rs 5 per tablet as compared to the latest DPP4 inhibitors, globally.

A K S Rawat said, “The 6-crore adult Indian population has been found to be diabetic and there is no effective solution for diabetes as yet. We are sure that eminent medical professionals will recommend BGR-34 to their patients suffering from type 2 Diabetes mellitus for quicker and consistent response. CSIR’s premier research institutions have developed and established the efficacy of BGR-34.”

For all the latest India News, download Indian Express App

    Live Cricket Scores & Results